BioStock: Alzinova signs Letter of Intent with Saudi Arabian stakeholder
Saudi Arabia has emerged as one of the world's most capital-strong markets for biotech investments. Swedish Alzinova is now positioning itself to capitalize on this opportunity through a Letter of Intent with a leading local healthcare provider. The objective is to secure both clinical infrastructure and financing for the upcoming Phase II study of the vaccine candidate ALZ-101.
Read the full interview at biostock.se:
Alzinova signs letter of intent with player in Saudi Arabia
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/